Louis P Garrison

Summary

Publications

  1. doi request reprint Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 204:S124-32. 2011
  2. doi request reprint BMI trajectories among the severely obese: results from an electronic medical record population
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Obesity (Silver Spring) 20:2107-12. 2012
  3. ncbi request reprint Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington
    Surg Obes Relat Dis 9:701-5. 2013
  4. doi request reprint Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity
    Bruce C M Wang
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, H375Q, Seattle, WA, 98195, USA
    Eur J Health Econ 15:253-63. 2014
  5. doi request reprint Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Value Health 16:823-9. 2013
  6. pmc Estimating the costs of induced abortion in Uganda: a model-based analysis
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
    BMC Public Health 11:904. 2011
  7. doi request reprint Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
    Gregory F Guzauskas
    Center for Genomics and Healthcare Equality, University of Washington, Seattle, Washington, USA
    Genet Med 15:84-7. 2013
  8. ncbi request reprint Systematic review of comparative effectiveness data for oncology orphan drugs
    Mindy M Cheng
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Am J Manag Care 18:47-62. 2012
  9. pmc Potential cost-effectiveness of universal access to modern contraceptives in Uganda
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e30735. 2012
  10. pmc Examining the BMI-mortality relationship using fractional polynomials
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    BMC Med Res Methodol 11:175. 2011

Collaborators

Detail Information

Publications32

  1. doi request reprint Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    J Infect Dis 204:S124-32. 2011
    ..Funders need to prioritize their scarce research and development resources. This article demonstrates the usefulness of cost-effectiveness analysis to support these decisions...
  2. doi request reprint BMI trajectories among the severely obese: results from an electronic medical record population
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington, USA
    Obesity (Silver Spring) 20:2107-12. 2012
    ..Our results also suggest that once the 35 BMI threshold is reached, individuals will continue to remain severely obese, especially at younger ages...
  3. ncbi request reprint Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington
    Surg Obes Relat Dis 9:701-5. 2013
    ..Our objective was to estimate the amount of postoperative weight loss, change in co-morbidity status, and complications after LAGB. The setting was LAGB surgical centers in Washington state...
  4. doi request reprint Cost-effectiveness of bariatric surgical procedures for the treatment of severe obesity
    Bruce C M Wang
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Ave, H375Q, Seattle, WA, 98195, USA
    Eur J Health Econ 15:253-63. 2014
    ..One-third of Americans are obese and an increasing number opt for bariatric surgery. This study estimates the cost-effectiveness of common bariatric surgical procedures from a healthcare system perspective...
  5. doi request reprint Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach
    Vincent W Lin
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195, USA
    Value Health 16:823-9. 2013
    ..To estimate the relationship between health utilities and body mass index (BMI) among a cohort of obese patients who underwent laparoscopic adjustable gastric banding (LAGB)...
  6. pmc Estimating the costs of induced abortion in Uganda: a model-based analysis
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, WA, USA
    BMC Public Health 11:904. 2011
    ..These abortions, which are usually unsafe, lead to a high rate of severe complications and use of substantial, scarce healthcare resources. This study was performed to estimate the costs associated with induced abortions in Uganda...
  7. doi request reprint Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy
    Gregory F Guzauskas
    Center for Genomics and Healthcare Equality, University of Washington, Seattle, Washington, USA
    Genet Med 15:84-7. 2013
    ..We evaluated genetic services stakeholder opinions on the potential usefulness of decision-analytic modeling to inform coverage decisions, and asked them to identify genetic tests for decision-analytic modeling studies...
  8. ncbi request reprint Systematic review of comparative effectiveness data for oncology orphan drugs
    Mindy M Cheng
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA 98195 7630, USA
    Am J Manag Care 18:47-62. 2012
    ..To systematically assess clinical and economic evidence for oncology orphan drugs marketed in the United States and to highlight the challenges and opportunities for evidence development within this pharmaceutical category...
  9. pmc Potential cost-effectiveness of universal access to modern contraceptives in Uganda
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, School of Public Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 7:e30735. 2012
    ....
  10. pmc Examining the BMI-mortality relationship using fractional polynomials
    Edwin S Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    BMC Med Res Methodol 11:175. 2011
    ..This approach was then compared against other commonly used regression models...
  11. doi request reprint Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    J Infect Dis 204:S116-23. 2011
    ..Before an elimination program is initiated, it is important to consider its potential economic impact, including its cost-effectiveness...
  12. doi request reprint Economic evaluation of capecitabine as adjuvant or metastatic therapy in colorectal cancer
    Jennie H Best
    Department of Pharmacy, University of Washington, Box 357630, Seattle, WA 98195, USA
    Expert Rev Pharmacoecon Outcomes Res 10:103-14. 2010
    ..e., providing good value for money) but, furthermore, would actually be cost saving in the majority of country settings...
  13. doi request reprint Preference values associated with stage III colon cancer and adjuvant chemotherapy
    Jennie H Best
    University of Washington, Seattle, WA, USA
    Qual Life Res 19:391-400. 2010
    ..To elicit preference values for health states associated with Stage III colon cancer (CRC) and to explore the effect of neuropathy associated with current adjuvant treatment...
  14. pmc Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e18193. 2011
    ..The PRP was started to reduce workforce shortages and optimize patient care by substituting pharmacy visits for SOC involving monthly physician visits for accessing antiretroviral medicines...
  15. pmc The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007)
    William B Wong
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, WA, USA
    Contemp Clin Trials 33:1117-23. 2012
    ..The objective of this study was to assess the value of research of the RxPONDER study, an ongoing comparative effectiveness RCT designed to evaluate a 21-gene profile in early stage, node-positive breast cancer...
  16. pmc Paying for personalized care: cancer biomarkers and comparative effectiveness
    Rahber Thariani
    Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Mol Oncol 6:260-6. 2012
    ..Evidence of comparative effectiveness can also help support value-based reimbursement of cancer biomarkers and treatment strategies as means of paying for personalized medicine...
  17. pmc Stakeholder perspectives on a risk-benefit framework for genetic testing
    Joshua A Roth
    Department of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Public Health Genomics 14:59-67. 2011
    ..The meeting's findings emphasize the potential utility of risk-benefit analysis in genetic test evaluation, and highlight key areas for future research and stakeholder consensus-building...
  18. ncbi request reprint Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, Washington, USA
    Cancer 110:489-98. 2007
    ..A cost-effectiveness analysis was performed to assess clinical and economic implications of adding trastuzumab to adjuvant chemotherapy, based upon joint analysis of NSABP B-31 and NCCTG N9831 trials...
  19. doi request reprint A framework for assessing the economic value of pharmacovigilance in low- and middle-income countries
    Joseph B Babigumira
    Global Medicines Program, Department of Global Health, University of Washington, Harris Hydraulics Building, Room 319, 1705 NE Pacific St, Box 357965, Seattle, WA, 98195 7965, USA
    Drug Saf 37:127-34. 2014
    ....
  20. ncbi request reprint Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, Box 357630, Seattle, WA, 98195 7630, USA
    Appl Health Econ Health Policy 12:231-8. 2014
    ..The long-term viability and growth of these arrangements will rest in the ability of the parties to develop mutually beneficial arrangements that entail minimal administrative burden in their development and implementation. ..
  21. doi request reprint The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision
    David R Flum
    University of Washington Schools of Medicine, Pharmacy and Public Health, Seattle, WA, USA
    Ann Surg 254:860-5. 2011
    ..To determine the impact of the Centers for Medicare and Medicaid Services' (CMS) bariatric surgery national coverage decision (NCD) on the use, safety, and cost of care CMS beneficiaries...
  22. doi request reprint Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score
    Sean D Sullivan
    University of Washington, Seattle, WA 98195 7630, USA
    J Med Econ 14:609-16. 2011
    ..The first approach identified high risk patients using impaired fasting glucose (IFG). The second approach used the PreDx Diabetes Risk Score (DRS) to further stratify IFG patients into high-risk and moderate-risk groups...
  23. doi request reprint Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers
    Josh J Carlson
    Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 7630, United States
    Health Policy 96:179-90. 2010
    ..To identify, categorize and examine performance-based health outcomes reimbursement schemes for medical technology...
  24. pmc The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenan
    Louis P Garrison
    University of Washington School of Pharmacy, Box 357630, Seattle, Washington 98195, USA
    Oncologist 18:27-36. 2013
    ..We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R...
  25. ncbi request reprint Innovation in diagnostic imaging services: assessing the potential for value-based reimbursement
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Acad Radiol 18:1109-14. 2011
    ..The authors examine how and whether value-based reimbursement for diagnostic imaging services might better reward innovation explicitly for expected improvements in health and economic outcomes...
  26. doi request reprint The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
    Josh J Carlson
    School of Pharmacy, University of Washington, Seattle, WA 98195, USA
    Value Health 12:20-7. 2009
    ..The objective of this study was to evaluate the potential cost-utility of implementing epidermal growth factor receptor (EGFR) testing before initiating second-line therapy for advanced refractory non-small-cell lung cancer (NSCLC)...
  27. ncbi request reprint The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment
    Mindy M Cheng
    University of Washington, Seattle, WA 98195, USA
    J Med Econ 13:193-202. 2010
    ..To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance...
  28. doi request reprint The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer
    Louis P Garrison
    Department of Pharmacy, University of Washington, Health Sciences Building, Seattle, WA 98195 7630, USA
    Value Health 12:1118-23. 2009
    ....
  29. pmc Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda
    Joseph B Babigumira
    Pharmaceutical Outcomes Research and Policy Program, School of Pharmacy, University of Washington, Seattle, WA, USA
    BMC Health Serv Res 9:192. 2009
    ..We estimated the potential impact of task-shifting on costs of antiretroviral therapy (ART) and physician supply in Uganda. The study was performed at the Infectious Diseases Institute (IDI) clinic, a large urban HIV clinic...
  30. ncbi request reprint Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II
    Louis P Garrison
    University of Washington, Seattle, WA 98195 7630, USA
    Value Health 13:8-13. 2010
    ....
  31. doi request reprint Regulatory benefit-risk assessment and comparative effectiveness research: strangers, bedfellows or strange bedfellows?
    Louis P Garrison
    Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy, University of Washington, Seattle, WA 98195 7630, USA
    Pharmacoeconomics 28:855-65. 2010
    ..All said, it would seem that BRA and CER should be neither strangers nor strange bedfellows, but may need to be coaxed into being bedfellows...
  32. ncbi request reprint Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis
    Louis P Garrison
    Department of Pharmacy, University of Washington, Seattle, USA
    Health Aff (Millwood) 26:684-95. 2007
    ....